198 related articles for article (PubMed ID: 30540214)
1. Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease.
Young SM; Lim AYN; Lang SS; Lee KO; Sundar G
Orbit; 2019 Oct; 38(5):362-369. PubMed ID: 30540214
[No Abstract] [Full Text] [Related]
2. Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach.
Sipkova Z; Insull EA; David J; Turner HE; Keren S; Norris JH
Clin Endocrinol (Oxf); 2018 Dec; 89(6):834-839. PubMed ID: 30103255
[TBL] [Abstract][Full Text] [Related]
3. The role of intravenous methylprednisolone immunosuppression in the management of active thyroid eye disease.
Tambe K; Bhargava J; Tripathi A; Gregory M; Burns J; Sampath R
Orbit; 2010 Oct; 29(5):227-31. PubMed ID: 20812826
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of combined parenteral and oral steroid therapy in Graves' orbitopathy.
Nedeljkovic Beleslin B; Ciric J; Zarkovic M; Stojkovic M; Savic S; Knezevic M; Stankovic B; Trbojevic B
Hormones (Athens); 2014; 13(2):222-8. PubMed ID: 24776622
[TBL] [Abstract][Full Text] [Related]
5. Tear inflammatory cytokines and ocular surface changes in patients with active thyroid eye disease treated with high-dose intravenous glucocorticoids.
Xu N; Cui Y; Fu D; Sun F
J Endocrinol Invest; 2020 Jul; 43(7):901-910. PubMed ID: 31927748
[TBL] [Abstract][Full Text] [Related]
6. Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.
Miskiewicz P; Milczarek-Banach J; Bednarczuk T; Opolski G; Glowczynska R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261581
[TBL] [Abstract][Full Text] [Related]
7. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy.
Le Moli R; Baldeschi L; Saeed P; Regensburg N; Mourits MP; Wiersinga WM
Thyroid; 2007 Apr; 17(4):357-62. PubMed ID: 17465867
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with the efficacy of intravenous methylprednisolone in moderate-to-severe and active thyroid-associated ophthalmopathy: A single-centre retrospective study.
Hu S; Wang Y; He M; Zhang M; Ding X; Shi B
Clin Endocrinol (Oxf); 2019 Jan; 90(1):175-183. PubMed ID: 30229982
[TBL] [Abstract][Full Text] [Related]
9. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy.
Zhu W; Ye L; Shen L; Jiao Q; Huang F; Han R; Zhang X; Wang S; Wang W; Ning G
J Clin Endocrinol Metab; 2014 Jun; 99(6):1999-2007. PubMed ID: 24606088
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy.
Currò N; Covelli D; Vannucchi G; Campi I; Pirola G; Simonetta S; Dazzi D; Guastella C; Pignataro L; Beck-Peccoz P; Ratiglia R; Salvi M
Thyroid; 2014 May; 24(5):897-905. PubMed ID: 24417307
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate as an Adjuvant in Severe Thyroid Eye Disease: Does It Really Work as a Steroid-Sparing Agent?
Yong KL; Chng CL; Ming Sie N; Lang S; Yang M; Looi A; Choo CT; Shen S; Seah LL
Ophthalmic Plast Reconstr Surg; 2019; 35(4):369-373. PubMed ID: 30624412
[TBL] [Abstract][Full Text] [Related]
13. RETROSPECTIVE ANALYSIS OF PATIENTS WITH GRAVES ORBITOPATHY TREATED BY PULSES OF METHYLPREDNISOLONE, WITH A FOCUS ON ADVERSE EVENTS.
Schovanek J; Cibickova L; Karhanova M; Kovarova D; Frysak Z; Karasek D
Endocr Pract; 2018 Jul; 24(7):652-657. PubMed ID: 30048166
[TBL] [Abstract][Full Text] [Related]
14. What is the aim of immunosuppressive treatment in patients with graves' orbitopathy?
Yang M; Wiersinga WM; Soeters MR; Mourits MP
Ophthalmic Plast Reconstr Surg; 2014; 30(2):157-61. PubMed ID: 24492732
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone: a comparison of two dosing regimens.
Sánchez-Ortiga R; Moreno-Pérez O; González Sánchez V; Arias Mendoza N; Mauri Dot M; Alfayate Guerra R; López Macia A; Picó Alfonso A
Endocrinol Nutr; 2009 Mar; 56(3):118-22. PubMed ID: 19627724
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease.
Ayabe R; Rootman DB; Hwang CJ; Ben-Artzi A; Goldberg R
Ophthalmic Plast Reconstr Surg; 2014; 30(5):415-9. PubMed ID: 24978425
[TBL] [Abstract][Full Text] [Related]
17. High dose intravenous methylprednisolone pulse therapy causes transient increase of serum calcium and phosphate levels.
Rymuza J; Popow M; Bednarczuk T; Miśkiewicz P
Pol Merkur Lekarski; 2019 Sep; 47(279):91-94. PubMed ID: 31557136
[TBL] [Abstract][Full Text] [Related]
18. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
Zivadinov R; Rudick RA; De Masi R; Nasuelli D; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
Neurology; 2001 Oct; 57(7):1239-47. PubMed ID: 11591843
[TBL] [Abstract][Full Text] [Related]
19. A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy.
Kemchoknatee P; Tangon D; Srisombut T
BMC Ophthalmol; 2023 Jan; 23(1):32. PubMed ID: 36690985
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate.
Al-Mayouf S; Al-Mazyed A; Bahabri S
Clin Rheumatol; 2000; 19(2):138-41. PubMed ID: 10791626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
